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Abstract: 1 
 2 
Objectives: Dietary nitrate (NO3-) supplementation and ischaemic preconditioning (IPC) can 3 
independently improve exercise performance. The purpose of this study was to explore whether 4 
NO3- supplementation, ingested prior to an IPC protocol, could synergistically enhance 5 
parameters of exercise.  6 
Design: Double-blind randomized crossover trial. 7 
Methods: Ten competitive male cyclists (age 34 ± 6 years, body mass 78.9 ± 4.9 kg, V̇O2peak 8 
55 ± 4 mL·kg·min-1) completed an incremental exercise test followed by three cycling trials 9 
comprising a square-wave submaximal component and a 16.1 km time-trial. Oxygen uptake 10 
(V̇O2) and muscle oxygenation kinetics were measured throughout. The baseline (BASE) trial 11 
was conducted without any dietary intervention or IPC. In the remaining two trials, participants 12 
received 3 × 5 min bouts of lower limb bilateral IPC prior to exercise. Participants ingested 13 
NO3--rich gel (NIT+IPC) 90 min prior to testing in one trial and a low NO3- placebo in the other 14 
(PLA+IPC). Plasma NO3- and nitrite (NO2-) were measured immediately before and after 15 
application of IPC. 16 
Results: Plasma [NO3-] and [NO2-] were higher before and after IPC in NIT+IPC compared to 17 
BASE (P<0.001) but did not differ between BASE and PLA+IPC. There were no differences 18 
in V̇O2 kinetics or muscle oxygenation parameters between trials (all P>0.4). Performance in 19 
the time-trial was similar between trials (BASE 1343 ± 72 s, PLA+IPC 1350 ± 75 s, NIT+IPC 20 
1346 ± 83 s, P=0.98). 21 
Conclusions: Pre-exercise IPC did not improve sub-maximal exercise or performance 22 
measures, either alone or in combination with dietary NO3- supplementation.  23 
 24 
Keywords: Nitric oxide; blood flow; hyperaemia; nitrite; exercise 25 
 26 
 27 
  28 
 2 
Introduction 29 
Ischemic preconditioning (IPC) typically consists of blood flow occlusion followed by a period 30 
of reperfusion which is repeated over 2 – 4 cycles. Whilst originally utilized to suppress the 31 
damaging effects of prolonged ischemia to an organ or skeletal muscle, IPC has recently been 32 
adopted as a preparation tool for performance enhancement1. Although the precise 33 
mechanism(s) by which IPC can improve exercise performance are not fully understood, recent 34 
evidence demonstrates that IPC causes an increase in circulating nitrite (NO2-) via shear stress 35 
activation of nitric oxide (NO) by endothelial NO synthase (eNOS), resulting in subsequent 36 
physiological effects2,3. For example, remote limb IPC provides systemic whole-body 37 
protection beyond the site of ischemia and when applied to either the upper or lower limbs, can 38 
lead to enhanced muscle blood flow and thus oxygen (O2) delivery, and an improved efficiency 39 
during aerobic respiration4–6. These physiological factors may account for the purported 40 
ergogenic effects of IPC on exercise performance7,8. 41 
 42 
Dietary nitrate (NO3-) supplementation can also increase circulating plasma NO2- via the 43 
enterosalivary NO3-– NO2- – NO pathway9. During this process, facultative anaerobic bacteria 44 
residing in the oral cavity reduce NO3- to NO2- which can be further reduced to NO in hypoxic 45 
or acidic conditions10. Studies have demonstrated that dietary NO3- supplementation can induce 46 
vasodilation, reduce the O2 cost (V̇O2) of exercise and, in some cases, improve exercise 47 
performance10,11. Importantly, these effects appear more pronounced in hypoxic or acidic 48 
conditions12, such as during high-intensity exercise or at altitude13. Another potential synergetic 49 
interaction between IPC and NO3- is the time course of their effects. It has been shown that 50 
plasma NO metabolites reach peak levels 1-3 h following ingestion of  NO3-, with levels 51 
returning to baseline levels after 6-8 hours14. Similarly, IPC has been shown to offer an early 52 
window of protection 1-2 h post-IPC for ischemic reperfusion injury15 and influence exercise 53 
performance up until 8 h after administration16. Given that IPC and ingestion of NO3- can both 54 
independently increase NO2- and improve exercise performance, it is conceivable that a 55 
 3 
combination of these interventions may lead to a more pronounced increase in NO availability 56 
and improvement in exercise performance.  57 
 58 
The purpose of this study therefore, was to determine the combined effects of dietary NO3- 59 
supplementation and pre-exercise IPC of the lower limbs on the physiological responses to sub-60 
maximal exercise and time-trial performance. We hypothesized that IPC combined with dietary 61 
NO3- supplementation would result in a cumulative rise in plasma NO2- and improve muscle 62 
oxygenation, V̇O2 kinetics, and exercise performance compared to a control or IPC alone.  63 
 64 
Methodology 65 
Ten competitive, trained male cyclists (age 34 ± 6 years, body mass 78.9 ± 4.9 kg, V̇O2peak: 55 66 
± 4 mL·kg·min-1, ventilatory threshold: 272 ± 30 W, maximum work rate: 424 ± 42 W) 67 
volunteered and provided written informed consent to participate in the study. The participants 68 
had all previously participated in exercise testing in a laboratory. All participants met the 69 
following inclusion criteria: cycling training for a minimum of two years, training at least three 70 
days per week, and racing on a regular basis including time-trials17. The study was granted 71 
ethical approval by the School of Science and Sport Ethics Committee at the University of the 72 
West of Scotland, and all procedures were conducted in accordance with the Declaration of 73 
Helsinki.  74 
 75 
The experimental design is outlined in Figure 1. Each participant visited the laboratory on four 76 
separate occasions over a 4–6 week period and all visits were interspersed with a minimum 1-77 
week recovery period. Participants arrived at the laboratory at least 3 h post-prandial and 78 
completed each of their trials at the same time of day (± 2 h) in a temperature-controlled 79 
environment (20.5 ± 1.6°C). During visit 1, standard anthropometric measures were assessed 80 
prior to completion of a continuous graded incremental exercise test to exhaustion at a rate of 81 
30 W·min-1 on an electronically braked cycle ergometer (Lode Excalibur, Groningen, The 82 
Netherlands) for determination of ventilatory threshold and VO2peak. The second visit was a 83 
 4 
baseline performance trial (BASE) which was followed by two further experimental 84 
performance trials.  85 
 86 
The BASE trial followed a similar protocol to the experimental trials but was not preceded by 87 
any intervention. The experimental performance trials were preceded by ingestion of either 2 × 88 
NO3- gels (NIT+IPC; Science in Sport Go+ Nitrates, Lancashire, UK, ~ 500 mg NO3-) or a low 89 
NO3- placebo gel matched for taste and texture (PLA+IPC; Science in Sport bespoke gel, ~0.001 90 
mg NO3-) 90 min before arrival at the laboratory18. This dose of NO3- has been previously shown 91 
to improve cycling performance13. The supplementation regimen was conducted using a 92 
double-blind randomized crossover design. The allocation of supplementation order was 93 
arranged using a random sequence generation and this was not revealed to the researchers until 94 
after analyses had been completed. Participants were asked to refrain from the consumption of 95 
alcohol and caffeine and to avoid any strenuous exercise for 24 h before each trial. In addition, 96 
they were requested not to use anti-bacterial mouthwash for the entire duration of the study.  97 
 98 
During the NIT and PLA trials, each participant received four cycles of IPC. The IPC protocol 99 
for each cycle comprised 5 min bilateral occlusion of the lower-limbs at a pressure of 180 100 
mmHg (E20 Rapid Cuff Inflator, Hokanson, Bellevue, WA) followed by 5 min reperfusion4,19. 101 
The pressure applied was >50 mmHg above resting systolic blood pressure (122 ± 6 mmHg), a 102 
stimulus which has been shown previously to improve exercise performance8. During the first 103 
cycle of IPC, visual confirmation of arterial occlusion was assessed using color Doppler 104 
imaging duplex with a L12 linear array transducer (Vivid 7 ultrasound machine, GE 105 
Electronics, Germany). During BASE, participants lay supine for 30 min to match the duration 106 
of IPC in the experimental trials. In each trial, participants initially lay supine for 15 min prior 107 
to obtaining a venous blood sample by venepuncture to ensure values were not influenced by 108 
postural changes20. Samples were collected in a vacutainer containing EDTA and spun 109 
immediately in a centrifuge for 10 min at 4000 rpm and 4oC before the plasma was extracted 110 
and frozen at -80oC. Plasma samples were later analysed for plasma [NO3-] and [NO2-] via gas-111 
 5 
phase chemiluminescence using methods previously described in detail21. A second venous 112 
blood sample was obtained immediately after completion of the IPC protocol in the PLA+IPC 113 
and NIT+IPC trials to determine the effects of IPC on NO2- and NO3- concentration.  114 
 115 
Participants then performed a 12 min square-wave bout of submaximal cycling exercise 116 
followed by a 16.1 km time-trial. The square-wave protocol consisted of 3 min rest in a seated 117 
position followed by 6 min cycling at an intensity of 80% ventilatory threshold and cadence of 118 
80 rpm followed by 3 min of seated recovery. The square-wave test was completed on an 119 
electronically braked cycle ergometer (Lode Excalibur, Groningen, The Netherlands) and 120 
enabled a standardized comparison of muscle oxygenation and V̇O2 kinetics between trials. 121 
Pulmonary gas exchange and ventilation were continuously measured breath-by-breath for the 122 
full duration of the square wave bout (Medgraphics Ultima, MGC Diagnostics, MN, USA) but 123 
not during the time-trial. The coefficient of variation (CoV) for the measurement of V̇O2 during 124 
moderate intensity cycling exercise in our lab is 2.4%. Near infrared spectroscopy (NIRS) was 125 
used to monitor local muscle oxygenation of the right vastus lateralis (NIRO 200NX, 126 
Hamamatsu Photonics KK, Hamamatsu, Japan). The NIRO uses three different wavelengths of 127 
near-infrared light (735, 810 and 850 nm) transmitted via a light emitting diode. The receiving 128 
diode measures the returning light from the tissue. The probes were placed in a manufacturer-129 
supplied black rubber holder (with a fixed emitter-detectors distance of 4 cm) and attached to 130 
the muscle with tape then secured using a transparent film dressing. The modified Beer-131 
Lambert method was used to detect changes in the concentration of oxygenated (HBO2) and 132 
deoxygenated (HHb) haemoglobin and total tissue haemoglobin and myoglobin (tHB = HBO2 133 
+ HHb). All NIRS data are expressed as arbitrary units based on the change from the baseline 134 
value. Tissue oxygenation index (TOI) was assessed using the spatially resolved spectroscopy 135 
technique. TOI is presented as a percentage and denotes the percentage ratio of HBO2 to tHB. 136 
The NIRS data were sampled at 5 Hz and then average for final minute of the resting phase and 137 
for the last 3 min of the exercise phase were analysed.  138 
 6 
The cycling time-trial was completed on an air and magnetically braked cycle ergometer 139 
(Wattbike Pro, Wattbike Ltd, Nottingham UK). Participants were instructed to cycle at a freely 140 
chosen cadence against an adjustable resistance in order to complete the time-trial in the fastest 141 
time possible. The Wattbike Pro cycle ergometer has been shown to have good reliability when 142 
used for repeated trials among trained participants22. The CoV for the measurement of 16.1 km 143 
time-trial performance in trained cyclists on the Wattbike cycle ergometer in our lab is 0.9%. 144 
Participants received verbal feedback on the distance covered upon completion of each 145 
kilometre and every 250 m for the final kilometre.  146 
 147 
Breath by breath V̇O2 data from the square-wave test were filtered to remove values lying 4 148 
standard deviations (SD) from the local 5 breath mean. A non-linear least squares 149 
monoexponential model was fitted to the data from 0 s to 540 s to characterise the V̇O2 150 
responses to sub-maximal exercise using the following equation: 151 
 152 
V̇O2(t) = V̇O2rest + Ap [1 – e -(t/ τ)] 153 
 154 
Where V̇O2(t) is the V̇O2 at a given time point (t); V̇O2rest is the mean V̇O2 during rest; Ap is 155 
the amplitude (steady state V̇O2 - V̇O2rest) and τ the time constant.  156 
 157 
The reported mean response time (MRT) was calculated as the τ of the exponential function 158 
describing the rate of V̇O2 and represents the time elapsed for a 63% increase in V̇O2. The 159 
functional “gain” was also calculated by dividing the Ap by the work rate of the submaximal 160 
exercise.  161 
  162 
All analyses were carried out using RStudio Team (2016) Version  (RStudio: Integrated 163 
Development for R. RStudio, Inc., Boston, MA URL http://www.rstudio.com/) (see 164 
Supplementary methods) and Graph Pad Prism 7 (GraphPad Software Inc., San Diego, USA) 165 
for graph figures. One-way (condition) and two-way (condition and time) repeated-measures 166 
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analyses of variance were used to analyse the differences in plasma NO3- and NO2- 167 
concentrations, respiratory variables, muscle oxygenation, and time-trial outcomes. Post-hoc 168 
analyses of significant within-subject effects were performed with adjustments for multiple 169 
comparisons using the Bonferroni correction. Statistical significance was accepted when 170 
P<0.05. Results are expressed as mean ± SD and Δmean ± 95% confidence intervals (95% CI) 171 
where appropriate.  172 
 173 
Results 174 
Plasma NO2- and NO3- 175 
The effect of NO3- supplementation and IPC on plasma NO metabolites are presented in Figure 176 
2A and Figure 2B. There was a significant effect of NO3- supplementation on plasma [NO3-] 177 
and [NO2-] (both P<0.001). Prior to the administration of IPC, plasma [NO3-] and [NO2-] were 178 
significantly higher in the NIT+IPC condition compared to BASE (NO3- P<0.001, mean 179 
difference 375 μM, 95%CI 306–444 μM; NO2- P<0.001, mean difference 225 nM, 95%CI 85–180 
366 nM). There was no difference between the PLA+IPC and BASE conditions for either 181 
measure (NO3- P=0.991; NO2- P=0.991). Following the administration of IPC in the NIT+IPC 182 
condition, plasma [NO3-] and [NO2-] remained elevated compared to BASE (NO3- P<0.001, 183 
mean difference 342 μM, 95%CI 280–404 μM; NO2- P<0.001, mean difference 250 nM, 95%CI 184 
113–387 nM). Plasma [NO3-] and [NO2-] did not change from pre- to post-administration of 185 
IPC in the NIT+IPC condition (P=0.991, P=0.995, respectively). There were no differences in 186 
plasma [NO3-] and [NO2-] between PLA+IPC and BASE following IPC administration 187 
(P=1.00). These measures did not change from pre- to post-administration of IPC in the 188 
PLA+IPC trial (NO3- P=0.991; NO2- P=0.999).  189 
 190 
V̇O2 kinetics  191 
The pulmonary gas exchange data at rest and during submaximal exercise are presented in 192 
Table 1. The V̇O2 at rest and during steady state exercise was not different between conditions 193 
(P=0.400, P=0.401, respectively). There were also no differences in the MRT (P=0.400), 194 
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amplitude of the V̇O2 response (P=0.400), or the functional gain (decrease in V̇O2 relative to 195 
the increase in work rate) between trials (P=0.104).  196 
 197 
Muscle oxygenation 198 
The [HbO2], [HHb], and [TOI] data are presented in Table 1. There were no significant 199 
differences between the three trials at rest or during exercise in any of the NIRS variables (all 200 
P>0.9). 201 
 202 
Time-trial performance 203 
The time-trial completion time was not different between trials (BASE 1342.8 ± 72.3 s, 204 
PLA+IPC 1350 ± 74.5 s, NIT+IPC 1346.2 ± 83.3 s, P=0.978, Figure 2C).  205 
 206 
Discussion 207 
To our knowledge, this is the first study to investigate the influence of dietary NO3- 208 
supplementation combined with bilateral lower limb IPC on the physiological responses to 209 
submaximal cycling and exercise performance. In contrast to our hypothesis, IPC combined 210 
with NO3- supplementation increased the availability of plasma [NO2-] from baseline but did 211 
not improve V̇O2 kinetics or muscle oxygenation during submaximal exercise or enhance 212 
cycling time-trial performance. 213 
 214 
Whilst IPC has been previously shown to improve some physiological responses to exercise 4-215 
6, there are conflicting findings19 suggesting IPC does not alter V̇O2 or V̇O2 kinetics. Cocking 216 
and colleagues23 recently reported that V̇O2 was lower during a cycling time-trial following the 217 
administration of IPC on the lower limbs. The authors suggested that local IPC may increase 218 
metabolic efficiency although this is likely task and/or intensity specific. The present study 219 
demonstrates further that pre-exercise administration of IPC does not improve muscle oxygen 220 
or reduce V̇O2 during sub-maximal exercise in well-trained cyclists. Moreover, the addition of 221 
an acute NO3- supplement to IPC also failed to alter these parameters. This finding is at odds 222 
 9 
with the majority of studies investigating dietary NO3- supplementation, although the lack of 223 
effect on V̇O2 is not entirely unprecedented24.  224 
 225 
The previously reported reductions in V̇O2 that result from either IPC or NO3- administration 226 
may be underpinned by an increased NO availability13 although the precise mechanism(s) 227 
remain unconfirmed. Whereas dietary NO3- is believed to augment NO availability via the 228 
enterosalivary NO3-–NO2-–NO pathway9, IPC may increase endogenous production of NO via 229 
eNOS stimulation2. Previous data suggests that an increased availability of NO may improve 230 
the efficiency of mitochondrial respiration25 and/or, reduce the energy cost of muscle force 231 
production26. It is also well-established that NO availability plays a role in the regulation of 232 
skeletal muscle blood flow and oxygenation during exercise27. In the present study, IPC did not 233 
increase plasma [NO2-] or [NO3-], which may explain the null effect on the outcome parameters 234 
assessed in this arm of the study. Conversely, the concentration of circulating NO metabolites 235 
did substantially increase during the NIT+IPC protocol but V̇O2 and muscle oxygenation did 236 
not differ from BASE. Whilst it can be argued that plasma [NO2-] and [NO3-] do not necessarily 237 
reflect whole body NO production, plasma [NO2-] is generally accepted to be the best marker 238 
of regional eNOS activity28. Whilst these findings are not readily explainable, a recent clinical 239 
study by Hauerslev and colleagues29 may shed some light on this discrepancy. These authors 240 
reported that IPC and treatment with glyceryl tri-nitrate (an NO donor) each independently 241 
protected against endothelial ischemic reperfusion injury. When combined, however, the 242 
protection was lost. Others have speculated that excess NO generated by NO donors can inhibit 243 
the neural signaling cascade that follows repeated bouts of ischemia and reperfusion30. This 244 
neural stimulation causes unidentified low-molecular-mass circulating hydrophobic factor(s) to 245 
be released into the blood stream which are suggested to underpin the cardioprotective effects 246 
of IPC31.  247 
 248 
In line with the absence of any alteration in muscle oxygenation and V̇O2 kinetics parameters, 249 
the application of IPC, either alone or in combination with dietary NO3- ingestion, did not have 250 
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any impact on cycling time-trial performance. Although previous research has shown that IPC 251 
can improve running7, rowing32 and swimming performance8 these ergogenic benefits are not 252 
always observed33. Dietary NO3- supplementation has also been shown to improve cycling 253 
performance in some trials13 but a recent meta-analysis suggests that the effects are trivial and 254 
non-significant11. The failure of either NIT+IPC or PLA-IPC to improve exercise performance 255 
may be explained by a number of factors. One cannot rule out that the beneficial effects of NO3- 256 
may have been abolished by co-administration of IPC29 as previously discussed. Alternatively, 257 
studies have noted a profound inter-individual variability in response to NO3- supplementation14 258 
which may be influenced by multiple factors. For example, Porcelli and colleagues34 have 259 
demonstrated that well-trained individuals, such as those used in the present study, have a 260 
blunted ergogenic response to NO3- supplementation. We have also demonstrated that the 261 
abundance of oral NO3--reducing bacteria can influence NO3-/NO2- pharmacokinetics9. 262 
However, the oral microbiome was not assessed in the present study and further research is 263 
required to determine how the abundance of these bacteria may influence the physiological 264 
responses to NO3- supplementation.  265 
 266 
One potential limitation of our study is that we did not include a sham condition for IPC. Indeed, 267 
a recurring issue in the field is the lack of an appropriate control measure for IPC research 268 
studies. In some studies, cuff inflation pressures of 20-50 mmHg were used as a sham treatment 269 
or cuffs were applied but not inflated1. However, the pressure differences are easily identifiable 270 
making it impossible to adequately blind participants to the treatment. This raises the possibility 271 
that IPC may exert either placebo or nocebo effects on exercise performance. One recent study 272 
demonstrated similar ergogenic effects were obtained using both IPC (occlusion at 220 mmHg) 273 
and a sham treatment (pressure of 20 mmHg)33. Moreover, IPC has been shown to improve 274 
exercise tolerance (as measured by time to exhaustion at 0.5 km/h above peak velocity) but this 275 
improvement is no greater than that obtained through a placebo intervention of therapeutic 276 
ultrasound35. On the whole this highlights the need for a better understanding of the mechanisms 277 
of IPC action and the potential mediators involved. 278 
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Based upon our findings, future studies may wish to examine different exercise intensities when 279 
combining IPC and dietary NO3- given that NO appears to best utilized in conditions of hypoxia, 280 
at a low pH, and in non-oxidative fast twitch fibers. Given IPC causes complete arterial 281 
occlusion it could prime muscle for exercise at extreme intensities where oxygen availability is 282 
significantly decreased. Griffin et al.36 have reported that IPC enhanced critical power (CP) in 283 
recreationally active males, building upon the rationale that CP has been shown to be improved 284 
when O2 delivery is enhanced via exposure to hyperoxia (FiO2 = 70%)37. If  IPC can indeed 285 
improve CP, this should theoretically translate to an improvement during exercise intensities 286 
between the heavy and severe domains. 287 
 288 
Conclusions 289 
This is the first study to investigate the effects of IPC in combination with dietary NO3- 290 
supplementation on the responses to submaximal cycling exercise and time-trial performance. 291 
While previous research has reported that IPC and NO3- can each independently have ergogenic 292 
effects, we found that IPC alone or in combination with NO3- did not alter V̇O2 kinetics, muscle 293 
oxygenation, or performance. Of note, there was no improvement in these outcomes in the 294 
NIT+IPC trial despite the protocol significantly increasing the availability of plasma NO2- 295 
metabolites. While further research is required to unravel the interactions between responses to 296 
IPC and NO3- supplementation, the present research study suggests that a combination of these 297 
interventions is not an efficacious method to improve 16.1 km cycling performance in well-298 
trained cyclists.  299 
 300 
  301 
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Practical Implications 302 
• Acute ingestion of dietary nitrate in combination with ischemic preconditioning does 303 
not influence oxygen kinetics, muscle oxygenation, or cycling performance 304 
• A combination of acute dietary nitrate and ischemic preconditioning is not an effective 305 
method of improving exercise performance. 306 
• Nitrate and nitrite bioavailability do not appear to be mediators of the physiological 307 
responses to ischemic preconditioning  308 
 309 
 310 
 311 
 312 
  313 
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Figure Legends 430 
Figure 1: Study design schematic outlining the three experimental conditions: Baseline 431 
(BASE), placebo plus ischemic preconditioning (PLA+IPC) and nitrate supplementation plus 432 
ischemic preconditioning (NIT+IPC). The BASE trial was completed first with the remaining 433 
two conditions completed in a randomized order. 434 
 435 
Figure 2: (A) Plasma nitrite and (B) plasma nitrate concentration before (PRE) and after 436 
(POST) application of the ischaemic preconditioning protocol during each performance trial. 437 
(C) 16.1km time-trial completion time, including individual completion times. Data are 438 
presented as mean ± SD. *denotes significant difference from BASE condition (P < 0.001). 439 
 440 
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Table 1. Oxygen Kinetics and NIRS variables during submaximal exercise test 453 
 454 
MRT = Mean response Time,  455 
NIRS = Near-infrared spectroscopy 456 
HHb = deoxyhaemoglobin 457 
HBO2 = oxyhaemoglobin 458 
TOI = Tissue Oxygenation Index 459 
 460 
 461 
Variable BASE PLA + IPC NIT + IPC 
  Difference 95 % CI Difference 95 % CI 
Oxygen Kinetics      
VO2 rest 
(ml·min-1) 
313 -24 -74, 25  -34 -83, 16 
VO2 exercise 
(ml·min-1) 
2999 -201 -490, 88  -123 -412, 166 
MRT (s) 41.9 0.6 -5.3, 6.4  0.5 -5.4, 6.4 
Amplitude 
(ml·min-1) 
2682 -177 -451, 97 -89 -363, 184 
Functional gain 
(ml·min·W-1) 
 
12.6 -0.8 -1.5, -0.1 -0.4 -1.1, 0.3 
NIRS (Arbitrary 
units) 
     
[HHb] rest 1.38 2.09 -4.32, 8.49 0.18 -6.23, 6.59 
[HHb] exercise 7.52 -0.08 -6.48, 6.33 -1.08 -7.49, 5.33 
[HbO2] rest 0.89 0.93 -3.91, 5.77 1.45 -3.39, 6.29 
[HbO2] exercise -4.84 -0.59 -5.43, 4.24 -0.57 -5.41, 4.27 
[TOI] rest 65.62 -2.11 -10.83, 6.62 -0.74 -9.47, 7.99 
[TOI] exercise 57.23 0.79 -7.94, 9.52 1.09 -7.64, 9.81 
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